As per the terms of the agreement, Sanofi Pasteur will fund collaborative research at Dyadic Netherland’s R&D facility in Wageningen, which will utilize Dyadic’s proprietary and patented C1 Platform Technology for certain vaccine applications.
The research is expected to be organized under the guidance of Dyadic Netherland general manager Wim van der Wilden with EnGen Bio president and CEO Mark Alfenito.
Dyadic president and CEO Mark Emalfarb said they are very pleased to have the opportunity to work with Sanofi Pasteur and EnGen Bio to further demonstrate the utility of their C1 technology for certain vaccine applications.